Navitoclax
Navitoclax is a small molecule inhibitor that targets Bcl-2 family proteins, which are known to play a significant role in the regulation of apoptosis. It was developed by AbbVie and Genentech, two leading pharmaceutical companies. Navitoclax is currently being investigated for its potential use in the treatment of various cancers and fibrotic diseases.
History[edit | edit source]
Navitoclax was first synthesized in the early 2000s as part of a collaborative effort between AbbVie and Genentech. The compound was designed to inhibit Bcl-2 family proteins, which are often overexpressed in cancer cells and contribute to tumor growth and resistance to chemotherapy.
Mechanism of Action[edit | edit source]
Navitoclax works by binding to Bcl-2 family proteins and inhibiting their function. These proteins normally act to prevent apoptosis, or programmed cell death. By inhibiting these proteins, Navitoclax allows cells to undergo apoptosis, which can lead to the reduction of tumor size and potentially slow the progression of the disease.
Clinical Trials[edit | edit source]
Navitoclax has been tested in several clinical trials for various types of cancer, including chronic lymphocytic leukemia (CLL), small cell lung cancer (SCLC), and myelofibrosis. In these trials, Navitoclax has shown promise in reducing tumor size and improving patient outcomes. However, further research is needed to fully understand the potential benefits and risks of this treatment.
Side Effects[edit | edit source]
Like all drugs, Navitoclax can cause side effects. The most common side effects reported in clinical trials include nausea, vomiting, diarrhea, and fatigue. In some cases, Navitoclax can also cause serious side effects, such as thrombocytopenia (low platelet count) and neutropenia (low white blood cell count). Patients should discuss these potential risks with their healthcare provider before starting treatment with Navitoclax.
Future Directions[edit | edit source]
Research on Navitoclax is ongoing, with several clinical trials currently in progress. These trials aim to further evaluate the safety and efficacy of Navitoclax in different types of cancer and fibrotic diseases. In addition, researchers are investigating the potential of Navitoclax in combination with other cancer treatments, such as immunotherapy and targeted therapies.
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD